Mustang Bio Reports the US FDA’s Acceptance of IND Application for MB-109 to Treat Recurrent Glioblastoma and High-Grade Astrocytoma
Shots:
- The US FDA has accepted the IND application to initiate a P-I trial evaluating the safety, tolerability & efficacy of MB-109, a novel combination of MB-101 and MB-108 at the City of Hope & the University of Alabama at Birmingham in adult patients with recurrent GBM and high-grade astrocytomas
- The study is expected to begin enrolling patients in 2024. The preclinical data supported the combination therapy to optimize results to treat recurrent GBM, presented at AACR 2022 and ongoing P-I trial have shown both to be well tolerated separately
- MB-109 {MB-101 (IL-13Rα2 targeted CAR-T cells) + MB-108 oncolytic virus} is designed to leverage MB-108 to make cold tumors “hot” and improve the efficacy of MB-101 CAR-T cell therapy
Ref: Mustang Bio | Image: Mustang Bio
Related News:- Mustang Bio Presents Updated P-I/II Trial Results of MB-106 for the Treatment of Waldenstrom Macroglobulinemia at EHA 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
